About Porton

Founded in 2005, Porton Pharma Solutions provides end-to-end, customized R&D and GMP manufacturing services to pharmaceutical and biotech companies, as well as research institutions worldwide, spanning the entire drug lifecycle from pre-clinical development to commercialization. Our capabilities cover both drug substances (APIs) and drug products across multiple modalities, including Small Molecules, TIDES, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products. As of June 30, 2026, Porton had over 4,400 employees globally, built partnerships with more than 1,500 customers, and successfully delivered approximately 6,000 projects. We are committed to a customer-centric approach, delivering innovative and reliable global CDMO solutions, enabling earlier access to good medicines.